Evommune(EVMN) - 2025 Q3 - Quarterly Results

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized to deliver on key milestones following completion of initial public offering (IPO), raising $172.5 million in gross proceeds, including the full exercise of the underwriters' option to purchase additional shares Palo Alto, Calif., December 11, 2025 – Evo ...